In a majority of case, Coronavirus enters human body through the nose. Fighting and stopping the virus at the entry point is quite logical and should be effective. Keeping that in mind Bharat Biotech, developed and got approved the much awaited nasal Covid 19 vaccine booster that has shown impressive results in tests and trials.
Intranasal Vaccine – Fight Against Covid gets a boost
As new variants of Covid 19 are spreading like anything and reports from China are scary, the development of something more powerful and effective to fight the virus, was on high priority. The developers of the drug took the challenge and produced a seemingly game changer in the form of iNCOVACC intranasal vaccine. Obviously, it is needle-free and painless. It is the first nasal vaccine to be administered in drops.
Breaking the Cycle of Transmission
Nasal Mucosa is the first place where viral infection occurs, multiplies and spreads. The nasal vaccine attacks the virus then and there and prevents the spread immediately. As the cycle of transmission breaks at the entry point, the it reduces the chances of mutation remarkably.
Not a replacement of intramuscular vaccine
However, it must be remembered that iNCOVACC is not going to be the replacement or substitute of existing intramuscular vaccine. It is just an addition protection or a booster that will strengthen your immunity and help you fight the new variants of Covid 19 virus more effectively.
When to take iNCOVACC
Ideally this nasal vaccine booster dose should be taken after 6 month after completion of the primary schedule of both doses of either Covishield or Covaxin.